MK2 inhibitory peptide delivered in nanopolyplexes prevents vascular graft intimal hyperplasia

Science Translational Medicine

Volumn 7, Issue 291, 2015, Pages

  Evans, Brian C ^a   Hocking, Kyle M ^a   Osgood, Michael J ^b   Voskresensky, Igor ^b   Dmowska, Julia ^a   Kilchrist, Kameron V ^a   Brophy, Colleen M ^b,c   Duvall, Craig L ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; HEAT SHOCK PROTEIN 27; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A0; MITOGEN ACTIVATED PROTEIN KINASE ACTIVATED PROTEIN KINASE 2 INHIBITORY PEPTIDE; NANOPARTICLE; NANOPOLYPLEX; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; MAP-KINASE-ACTIVATED KINASE 2; PEPTIDE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL GRAFT; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INHIBITION; DRUG SYNTHESIS; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MALE; NANOTECHNOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SAPHENOUS VEIN; SIGNAL TRANSDUCTION; VASCULAR GRAFT INTIMAL HYPERPLASIA; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; ENDOCYTOSIS; ENDOSOME; HYPERPLASIA; INTIMA; LYSOSOME; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RABBIT; SMOOTH MUSCLE CELL; SURGERY; TREATMENT OUTCOME;

ANIMALS; ENDOCYTOSIS; ENDOSOMES; HUMANS; HYPERPLASIA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYSOSOMES; MALE; MYOCYTES, SMOOTH MUSCLE; NANOPARTICLES; PEPTIDES; PHENOTYPE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RABBITS; SAPHENOUS VEIN; TREATMENT OUTCOME; TUNICA INTIMA; VASCULAR GRAFTING;

EID: 84930812527     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaa4549     Document Type: Article

References (38)

1. J. H. Alexander, G. Hafley, R. A. Harrington, E. D. Peterson, T. B. Ferguson Jr., T. J. Lorenz, A. Goyal, M. Gibson, M. J. Mack, D. Gennevois, R. M. Califf, N. T. Kouchoukos; PREVENT IV Investigators, Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: A randomized controlled trial. JAMA 294, 2446-2454 (2005).
2. K. C. Kent, B. Liu, Intimal hyperplasia-Still here after all these years! Ann. Vasc. Surg. 18, 135-137 (2004).
3. M. S. Conte, D. F. Bandyk, A. W. Clowes, G. L. Moneta, L. Seely, T. J. Lorenz, H. Namini, A. D. Hamdan, S. P. Roddy, M. Belkin, S.A. Berceli, R. J.DeMasi, R. H. Samson, S. S. Berman, Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J. Vasc. Surg. 43, 742-751 (2006).
4. P. C. Saunders, G. Pintucci, C. S. Bizekis, R. Sharony, K. M. Hyman, F. Saponara, F. G. Baumann, E. A. Grossi, S. B. Colvin, P. Mignatti, A. C. Galloway, Vein graft arterialization causes differential activation of mitogen-activated protein kinases. J. Thorac. Cardiovasc. Surg. 127, 1276-1284 (2004).
5. A. V. Bakin, C. Rinehart, A. K. Tomlinson, C. L. Arteaga, p38 mitogen-activated protein kinase is required for TGFb-mediated fibroblastic transdifferentiation and cell migration. J. Cell Sci. 115, 3193-3206 (2002).
6. J. C. Hedges, M. A. Dechert, I. A. Yamboliev, J. L.Martin, E. Hickey, L. A. Weber, W. T. Gerthoffer, A role for p38(MAPK)/HSP27 pathway in smooth muscle cell migration. J. Biol. Chem. 274, 24211-24219 (1999).
7. S. Rousseau, N. Morrice, M. Peggie, D. G. Campbell, M. Gaestel, P. Cohen, Inhibition of SAPK2a/p38 prevents hnRNP A0 phosphorylation by MAPKAP-K2 and its interaction with cytokine mRNAs. EMBO J. 21, 6505-6514 (2002).
8. D. M. Dambach, Potential adverse effects associated with inhibition of p38a/b MAP kinases. Curr. Top. Med. Chem. 5, 929-939 (2005).
9. K. Engel, A. Kotlyarov, M. Gaestel, Leptomycin B-sensitive nuclear export of MAPKAP kinase 2 is regulated by phosphorylation. EMBO J. 17, 3363-3371 (1998).
10. H.-F. Chen, L.-D. Xie, C.-S. Xu, Role of heat shock protein 27 phosphorylation in migration of vascular smooth muscle cells. Mol. Cell. Biochem. 327, 1-6 (2009).
11. P. Molnar, R. Perrault, S. Louis, P. Zahradka, The cyclic AMP response element-binding protein (CREB) mediates smooth muscle cell proliferation in response to angiotensin II. J. Cell Commun. Signal. 8, 29-37 (2014).
12. B. Ward, B. L. Seal, C. M. Brophy, A. Panitch, Design of a bioactive cell-penetrating peptide: When a transduction domain does more than transduce. J. Pept. Sci. 15, 668-674 (2009).
13. K. Hayess, R. Benndorf, Effect of protein kinase inhibitors on activity of mammalian small heat-shock protein (HSP25) kinase. Biochem. Pharmacol. 53, 1239-1247 (1997).
14. L. B. Lopes, C. M. Brophy, C. R. Flynn, Z. Yi, B. P. Bowen, C. Smoke, B. Seal, A. Panitch, P. Komalavilas, A novel cell permeant peptide inhibitor of MAPKAP kinase II inhibits intimal hyperplasia in a human saphenous vein organ culture model. J. Vasc. Surg. 52, 1596-1607 (2010).
15. C. R. Flynn, J. Cheung-Flynn, C. C. Smoke, D. Lowry, R. Roberson, M. R. Sheller, C. M. Brophy, Internalization and intracellular trafficking of a PTD-conjugated anti-fibrotic peptide, AZX100, in human dermal keloid fibroblasts. J. Pharm. Sci. 99, 3100-3121 (2010).
16. N. Murthy, J. R. Robichaud, D. A. Tirrell, P. S. Stayton, A. S. Hoffman, The design and synthesis of polymers for eukaryotic membrane disruption. J. Control. Release 61, 137-143 (1999).
17. S. Foster, C. L. Duvall, E. F. Crownover, A. S. Hoffman, P. S. Stayton, Intracellular delivery of a protein antigen with an endosomal-releasing polymer enhances CD8 T-cell production and prophylactic vaccine efficacy. Bioconjug. Chem. 21, 2205-2212 (2010).
18. I. R. Ruttekolk, J. J. Witsenburg, H. Glauner, P. H. M. Bovee-Geurts, E. S. Ferro, W. P. R. Verdurmen, R. Brock, The intracellular pharmacokinetics of terminally capped peptides. Mol. Pharm. 9, 1077-1086 (2012).
19. K. A. Mislick, J. D. Baldeschwieler, Evidence for the role of proteoglycans in cation-mediated gene transfer. Proc. Natl. Acad. Sci. U.S.A. 93, 12349-12354 (1996).
20. J. P. Richard, K. Melikov, H. Brooks, P. Prevot, B. Lebleu, L. V. Chernomordik, Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J. Biol. Chem. 280, 15300-15306 (2005).
21. C. E. Nelson, J. R. Kintzing, A. Hanna, J. M. Shannon, M. K. Gupta, C. L. Duvall, Balancing cationic and hydrophobic content of pegylated sirna polyplexes enhances endosome escape, stability, blood circulation time, and bioactivity in vivo. ACS Nano 7, 8870-8880 (2013).
22. M. Mietus-Snyder, A. Friera, C. K. Glass, R. E. Pitas, Regulation of scavenger receptor expression in smooth muscle cells by protein kinase C: A role for oxidative stress. Arterioscler. Thromb. Vasc. Biol. 17, 969-978 (1997).
23. M. Kalra, V. M. Miller, Early remodeling of saphenous vein grafts: Proliferation, migration and apoptosis of adventitial and medial cells occur simultaneously with changes in graft diameter and blood flow. J. Vasc. Res. 37, 576-584 (2000).
24. R. M. Zwolak, M. C. Adams, A. W. Clowes, Kinetics of vein graft hyperplasia: Association with tangential stress. J. Vasc. Surg. 5, 126-136 (1987).
25. A. Muto, A. Panitch, N. Kim, K. Park, P. Komalavilas, C. M. Brophy, A. Dardik, Inhibition of mitogen activated protein kinase activated protein kinase II with MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. Vascul. Pharmacol. 56, 47-55 (2012).
26. C. L. Duvall, A. J. Convertine, D. S. Benoit, A. S. Hoffman, P. S. Stayton, Intracellular delivery of a proapoptotic peptide via conjugation to a RAFT synthesized endosomolytic polymer. Mol. Pharm. 7, 468-476 (2010).
27. G.-L. Lee, Y.-W. Chang, J.-Y. Wu, M.-L. Wu, K. K. Wu, S.-F. Yet, C.-C. Kuo, TLR 2 induces vascular smooth muscle cell migration through cAMP response element-binding proteinmediated interleukin-6 production. Arterioscler. Thromb. Vasc. Biol. 32, 2751-2760 (2012).
28. K Nakanishi, Y Saito, N Azuma, T Sasajima, Cyclic adenosine monophosphate responseelement binding protein activation by mitogen-activated protein kinase-activated protein kinase 3 and four-and-a-half LIM domains 5 plays a key role for vein graft intimal hyperplasia. J. Vasc. Surg. 57, 182-93 (2013).
29. E. C. McLemore, D. J. Tessier, J. Thresher, P. Komalavilas, C. M. Brophy, Role of the small heat shock proteins in regulating vascular smooth muscle tone. J. Am. Coll. Surg. 201, 30-36 (2005).
30. J. G. Motwani, E. J. Topol, Aortocoronary saphenous vein graft disease: Pathogenesis, predisposition, and prevention. Circulation 97, 916-931 (1998).
31. L. Zhang, N. J. Freedman, L. Brian, K. Peppel, Graft-extrinsic cells predominate in vein graft arterialization. Arterioscler. Thromb. Vasc. Biol. 24, 470-476 (2004).
32. B. C. Cooley, J. Nevado, J. Mellad, D. Yang, C. St. Hilaire, A. Negro, F. Fang, G. B. Chen, H. San, A. D. Walts, R. L. Schwartzbeck, B. Taylor, J. D. Lanzer, A. Wragg, A. Elagha, L. E. Beltran, C. Berry, R. Feil, R. Virmani, E. Ladich, J. C. Kovacic, M. Boehm, TGF-b signaling mediates endothelial-tomesenchymal transition (EndMT) during vein graft remodeling. Sci. Transl. Med. 6, 227ra34 (2014).
33. P. R. Kapopara, J. von Felden, O. Soehnlein, Y. Wang, L. C. Napp, K. Sonnenschein, K. C. Wollert, B. Schieffer, M. Gaestel, J. Bauersachs, U. Bavendiek, Deficiency of MAPK-activated protein kinase 2 (MK2) prevents adverse remodelling and promotes endothelial healing after arterial injury. Thromb. Haemost. 112, 1264-1276 (2014).
34. Z. Jiang, L.Wu, B. L. Miller, D. R. Goldman, C. M. Fernandez, Z. S. Abouhamze, C. K. Ozaki, S. A. Berceli, A novel vein graft model: Adaptation to differential flow environments. Am. J. Physiol. Heart Circ. Physiol. 286, H240-H245 (2004).
35. A. C. Ruifrok, D. A. Johnston, Quantification of histochemical staining by color deconvolution. Anal. Quant. Cytol. Histol. 23, 291-299 (2001).
36. M. S. Ferrito, D. A. Tirrell, Poly(2-ethylacrylic acid), in Macromolecular Syntheses (Wiley, New York, 1992), vol. 11, pp. 59-62.
37. A. J. Convertine, D. S. W. Benoit, C. L. Duvall, A. S. Hoffman, P. S. Stayton, Development of a novel endosomolytic diblock copolymer for siRNA delivery. J. Control. Release 133, 221-229 (2009).
38. B. C. Evans, C. E. Nelson, S. S. Yu, K. R. Beavers, A. J. Kim, H. Li, H. M. Nelson, T. D. Giorgio, C. L. Duvall, Ex vivo red blood cell hemolysis assay for the evaluation of pH-responsive endosomolytic agents for cytosolic delivery of biomacromolecular drugs. J. Vis. Exp. 73, e50166 (2013).